Phibro Animal Health (PAHC) Cash & Equivalents (2013 - 2026)

Phibro Animal Health has reported Cash & Equivalents for 14 years, with the latest figure at $61.4 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 9.73% year-over-year to $61.4 million in Q2 2026; TTM through Jun 2026 was $61.4 million, a 9.73% decrease from a year earlier, with the FY2026 full-year figure at $61.4 million, down 9.73% from the prior year.
• Cash & Equivalents was $61.4 million for Q2 2026 at Phibro Animal Health, up from $54.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $76.3 million in Q3 2022, with the low at $33.0 million in Q4 2023.
• Average Cash & Equivalents over 5 years is $58.7 million, with a median of $60.9 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 51.81% in 2023, then soared 103.44% in 2024.
• Over 5 years, Cash & Equivalents stood at $68.4 million in 2022, then sank by 51.81% to $33.0 million in 2023, then jumped by 103.44% to $67.1 million in 2024, then slipped by 17.28% to $55.5 million in 2025, then climbed by 10.69% to $61.4 million in 2026.
• The last three Cash & Equivalents figures came in at $61.4 million (Q2 2026), $54.9 million (Q1 2026), and $55.5 million (Q4 2025), per Business Quant data.